Aropax 12.5mg or 25mg CR Tablets

    Aropax 12.5mg or 25mg CR Tablets

    S5


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder.

    Dosage (summary)

    Initial dose of 12.5 mg once daily, may be increased to 25 mg once daily based on clinical response.

    Onset of Action / Duration

    Therapeutic effects may be observed within 2 to 4 weeks of treatment initiation.

    Special Populations

    • Elderly patients
    • Patients with hepatic impairment
    • Patients with renal impairment

    Pregnancy & Breastfeeding

    Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Paroxetine is excreted in breast milk; caution is advised when administered to nursing mothers.

    Key Drug Interactions

    • MAO inhibitors
    • Other serotonergic drugs
    • Warfarin
    • NSAIDs
    • Alcohol

    Contraindications

    • Hypersensitivity to paroxetine or any component of the formulation
    • Concurrent use with monoamine oxidase inhibitors (MAOIs)
    • Use in patients with a history of serotonin syndrome

    Common side effects

    • Nausea
    • Dizziness
    • Somnolence
    • Insomnia
    • Dry mouth
    • Sexual dysfunction

    Counselling Points

    • Take the medication at the same time each day, with or without food.
    • Do not abruptly discontinue the medication without consulting your healthcare provider.
    • Report any unusual mood changes or suicidal thoughts immediately.
    • Avoid alcohol while taking this medication.

    Serious warnings

    • Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
    • May cause withdrawal symptoms if discontinued abruptly.
    • Monitor for signs of serotonin syndrome, especially when combined with other serotonergic agents.
    Important Disclaimer

    The Aropax 12.5mg or 25mg CR Tablets professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn